High-throughput *de novo* screening of receptor agonists with an automated single-cell analysis and isolation system

Author names

Nobuo Yoshimoto^{1,*}, Kenji Tatematsu², Masumi Iijima¹, Tomoaki Niimi¹, Andrés D. Maturana¹, Ikuo Fujii³, Akihiko Kondo⁴, Katsuyuki Tanizawa² & Shun'ichi Kuroda^{1,*}

Affiliations

¹ Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusaku, Nagoya, Aichi 464-8601, Japan;

² The Institute of Scientific and Industrial Research, Osaka University, Mihogaoka, Ibaraki, Osaka 567-0047, Japan;

³ Graduate School of Science, Osaka Prefecture University, Gakuen-cho, Naka-ku, Sakai, Osaka 599-8570, Japan;

⁴ Graduate School of Science and Technology, Kobe University, Rokkodai-cho, Nadaku, Kobe, Hyogo 657-8501, Japan.

Correspondence and requests for materials should be addressed to N. Y. (n-yosi44@agr.nagoya-u.ac.jp) & S. K. (skuroda@agr.nagoya-u.ac.jp).

Supplementary Information



Supplementary Figure S1. EGF-dependent homo-oligomerization of the EGFR in the yeast plasma membrane. (a) Molecular organizations of EGFRs in a split-ub assay. *TM*, transmembrane domain; *Nub*, N-terminal half of ub; *Cub*, C-terminal half of ub; *LexA*, DNA-binding domain of LexA; *VP16*, transcription-activating domain of VP16. (b) Split-ub assay. The yeast NMY51 strain co-expressing EGFR-Nub, EGFR-Cub-LexA-VP16 and either FLO42 or HA-EGF-FLO42 was spotted onto an SD plate (pH 7) containing glucose (*Glc*, for repression of *GAL1* promoter) or galactose (*Gal*, for induction of *GAL1* promoter). *ΔHis*, histidine-depleted SD medium; *X-gal*, X-gal-containing SD medium.



Supplementary Figure S2. Functional interaction of the EGFR with Grb2 and Shc1 in yeast cells. (a) Schematic drawing of the EGF signaling pathway reconstituted in yeast cells. N-terminal human Sos-fused forms of human adaptor proteins, Grb2 (*Grb*) and Shc1 (*Shc*), interact with phospho-EGFR in yeast cells. The membrane-recruited Sos is a guanine nucleotide-exchanging factor for human Ras, which converts yeast RAS from the GDP (inactive) form to the GTP (active) form and complements thermo-sensitive CDC25^{TS} in the yeast cdc25h strain, thereby allowing yeast cells to grow at 37 °C. (b) Complementation of thermo-sensitivity of the yeast cdc25h strain by EGF-dependent activation of the RAS signaling pathway. The yeast cdc25h strain co-expressing EGFR-V5 and either FLO42 or HA-EGF-FLO42 was spotted onto an SD plate and then incubated at 25 °C or 37 °C. *Grb2* and *Shc1* indicate the cdc25h strains expressing Sos-Grb2 and Sos-Shc1, respectively.

Supplementary Table S1. Nucleotide sequences of secondary helix-cording region
for EGFR agonist candidates

IUI LUI K ayu	nist candidates
Clone no.	nucleotide sequences*
1	AAGCTG <mark>TATTCG</mark> TTGAAA <mark>ATG</mark> AAGCTA <mark>CATAAG</mark> TTGAAAGCT
2	AAGCTG <mark>GATCCG</mark> TTGAAA <mark>ATT</mark> AAGCTA <mark>GAGTCG</mark> TTGAAAGCT
3	AAGCTG <mark>TCTTCG</mark> TTGAAA <mark>GCT</mark> AAGCTA <mark>TCTCAT</mark> TTGAAAGCT
4	AAGCTG <mark>CCTAAG</mark> TTGAAA <mark>CAT</mark> AAGCTA <mark>CCGACG</mark> TTGAAAGCT
5	AAGCTG <mark>AATCGT</mark> TTGAAA <mark>CAT</mark> AAGCTA <mark>TCGTTT</mark> TTGAAAGCT
6	AAACTG <mark>GATCCG</mark> TTGAAA <mark>ATT</mark> AAGCTA <mark>GAGTCG</mark> TTGAAAGCT
7	AAGCTG <mark>ATTTG</mark> TTTGAAA <mark>CAT</mark> AAGCTA <mark>ACGCCT</mark> TTGAAAGCT
8	AAGCTG <mark>ACTCCT</mark> TTGAAA <mark>AAG</mark> AAGCTA <mark>ACTGCT</mark> TTGAAAGCT
9	AAGCTG <mark>GATCCT</mark> TTGAAA <mark>ATT</mark> AAGCTA <mark>GAGTCG</mark> TTGAAAGCT
10	AAGCTG <mark>GATCCG</mark> TTGAAA <mark>ATT</mark> AAGCTA <mark>GAGTCG</mark> TTGAAAGCT
11	AAGCTG <mark>ACTCCT</mark> TTGAAA <mark>AAG</mark> AAGCTA <mark>ACTGCT</mark> TTGAAAGCT
12	AAGCTG <mark>ACTCCT</mark> TTGAAA <mark>AAG</mark> AAGCTA <mark>ACTGCT</mark> TTGAAAGCT
13	AAGCTG <mark>CCGCTT</mark> TTGAAA <mark>TCT</mark> AAGCTA <mark>TTGTCT</mark> TTGAAAGCT

* Identified nucleic acids are shown in red.

Supplementary Table S2. Amino acid sequences of EGFR agonist candidates

		· · · · · · · · · · · · · · · · · · ·
Clone no.	Amino acid sequences*	Notes
1	KL <mark>YS</mark> LK <mark>M</mark> KL <mark>HK</mark> LKA	No agonistic activity
2	KL <mark>DP</mark> LK <mark>I</mark> KL <mark>ES</mark> LKA	Identical to clones 6, 9 and 10
3	KL <mark>SS</mark> LK <mark>A</mark> KL <mark>SH</mark> LKA	
4	KL <mark>PK</mark> LK <mark>H</mark> KL <mark>PT</mark> LKA	No agonistic activity
5	KL <mark>NR</mark> LKHKL <mark>SF</mark> LKA	C
7	KL <mark>IC</mark> LK <mark>H</mark> KL <mark>TP</mark> LKA	
8	KL <mark>TP</mark> LK <mark>K</mark> KL <mark>TA</mark> LKA	Identical to clones 11 and 12
13	KL <mark>PL</mark> LK <mark>S</mark> KL <mark>LS</mark> LKA	

* Identified amino acid residues are shown in red.

Supplementary	Table S3. Amino acid sequences of	EG	FR r	nutants and H	LH peptides*	
Clone name	Amino acid sequences					Ref.
Human EGF	NSDSECPLSHDGYCLHDGVCMYIEALD	³ DKYA				37–39
G12Q Y13W	W					39 39
H16D Clone 114	DD			A	TGR-	39 40
m28 m123	K-V- YP-YRR	-R -S		A	TGP- RGR-	41 41
HLH	QAWAELAALEMELAALEGGGGGGGKL-	₃ ۲۲۴	₀ <−KL	LKAGGGS		
2	E)P	Ι	ES		
3	5	SS	Α	SH		
5	Ν	IR	Н	SF		
7	1	C	Н	ТР		
8	٦	ГР	K	ТА		
13	F	۲L	S	LS		

*Replaced amino acid residues in enhanced EGF mutants (G12Q, Y13W, H16D, clone 114, m28, m123) are shown. Essential amino acids for EGFR binding are indicated in red. Boxes and underline in HLH sequence indicate α -helix region and loop region, respectively.